TI
TSHA icon

Trexquant Investment’s Taysha Gene Therapies TSHA Stock Holding History

Trexquant Investment’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,548
Closed -$73K – 1845
2022
Q2 		$73K Sell
19,548
-51,935
-73% -$206K ﹤0.01% 1450
2022
Q1 		$466K Buy
71,483
+41,852
+141% +$313K 0.02% 797
2021
Q4 		$345K Buy
+29,631
New +$447K 0.02% 845

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Trexquant Investment's TSHA Position: Q3 2022 in Review

Trexquant Investment sold out of Taysha Gene Therapies (TSHA) in Q3 2022, closing a stake of 19,548 shares — an estimated $73K sold.

Trexquant Investment first reported a position in TSHA in Q4 2021 and held it in 3 quarters. The position peaked at $466K in Q1 2022. 54 funds tracked by Wall St. Rank hold TSHA as of Q3 2022.

  • Trexquant Investment reported no remaining Taysha Gene Therapies position as of Q3 2022 after selling out during the quarter.
  • Trexquant Investment sold 19,548 Taysha Gene Therapies shares in Q3 2022, an estimated $73K.
  • Trexquant Investment first reported a position in Taysha Gene Therapies in Q4 2021 and held it in 3 quarters.
  • Trexquant Investment's Taysha Gene Therapies position peaked at $466K in Q1 2022.
  • 54 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2022.

Based on Trexquant Investment's 13F filing for Q3 2022, filed 14 Nov 2022.